Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study

Por Petrioli, R, Pascucci, A, Conca, R, Chiriacò, G, Francini, E, Bargagli, G, Fiaschi, A I, Manganelli, A, De Rubertis, G, Barbanti, G, Ponchietti, R, Francini, G
Publicado em 2011